AI Science Tracker

EvoGradient evolves antimicrobial peptides active against resistant pathogens

Southeast University · 17 Jan 2025 · biology

Discovery

EvoGradient evolves antimicrobial peptides active against resistant pathogens

EvoGradient uses an explainable deep-learning potency model and virtual sequence evolution to optimize candidate antimicrobial peptides. Applied to peptides encoded by low-abundance human oral bacteria, it virtually evolved 32 candidates; the six most effective were synthesized and tested against multidrug-resistant pathogens. The authors report activity across carbapenem-resistant E. coli, K. pneumoniae and A. baumannii and vancomycin-resistant E. faecium; pep-19-mod reduced bacterial loads by more than 95% in mouse thigh-infection models under the reported systemic and local administrations. These are preclinical findings and do not establish human efficacy or safety.

Technology: Explainable deep-learning antimicrobial-peptide potency model with gradient-based virtual sequence evolution

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Six synthesized peptides were tested against multidrug-resistant pathogens; the authors also report pep-19-mod in-vivo testing in mouse thigh-infection models, with over 95% bacterial-load reduction under the described systemic and local administration.
  • Still unknown: Mouse infection outcomes do not establish human safety, dosing, efficacy or clinical translation; only six candidates from the 32 virtual evolutions were synthesized and tested.
  • AI role: EvoGradient predicts peptide potency and virtually modifies peptide sequences through gradient-based evolution; the workflow selected optimized candidates for synthesis and experimental testing.

Evidence sources: https://www.nature.com/articles/s41564-024-01907-3 · https://pubmed.ncbi.nlm.nih.gov/39825096/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 17 Nov 2026. Review scope: Primary Nature Microbiology indexed article text and primary PubMed abstract/metadata/affiliations; conclusions limited to reported preclinical assays..

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.